New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic blood test in reducing hospital length of stay (LOS) for heart failure (HF) patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought… Read More